Bolag
Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades år 2020 och har sitt huvudkontor i Lund.
Newbury has signed a new licence and supply agreement with one of its existing partners to register and launch Guanfacine in Sweden. Guanfacine, 1, 2, 3 and 4 mg prolonged release tablets, is a selective alpha2A-adrenergic receptor agonist used in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents.
Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Tofacitinib Newbury 5 mg and 10 mg film-coated tablets in Sweden as the first country in a Scandinavian registration procedure. Approvals in Norway and Denmark are expected to follow upon finalized national reviews.
Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Dalbavancin Newbury 500 mg powder for concentrate for solution for infusion in Sweden. No further country approvals are planned at this time.
Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Palbociclib Newbury tablets in Denmark as the first country in a Scandinavian registration procedure. Approvals in Sweden and Norway are expected to follow upon finalized national reviews.
The extraordinary general meeting of Newbury Pharmaceuticals AB took place on 15 April 2026. All decisions made by the general meeting are in accordance with the proposals presented in the notice.
Notice of Extraordinary General Meeting of Newbury Pharmaceuticals AB
Newbury Pharmaceuticals AB has agreed to extend and increase the existing loan agreement with AB Slädens Pensionsstiftelse nr 3, securing SEK 30 million in total financing through to 30 June 2027, and will convene an Extraordinary General Meeting to seek shareholder approval of the amendment.
Newbury has signed a contract with a new partner to register and launch Prucalopride in Sweden. Prucalopride, 1 and 2 mg tablets, is a selective, high affinity 5-HT4 receptor agonist which targets the impaired motility associated with chronic constipation, thus normalizing bowel movements.
Newbury Pharmaceuticals is pleased to announce that it has been awarded a 12-month tender for Pazopanib Newbury with the Danish procurement body Amgros, commencing on June 1, 2026.